According to preliminary information, annual EBITDA will be EUR 4-6m in 2024 (old guidance EUR 4-8m,...
In Q4-24, Eevia Health Plc (publ) (“Eevia” or “the Company”) launched a transformational restructuri...
SEK 120+7m retrofit order to be delivered in 2025-2035 Covers our '25e-'28e Retrofit assumptions, ~1...
Q4e: 15% organic sales growth y-o-y, 11% adj. EBITA margin Expect a solid Q4, partly on light comps ...
Redeye comments on Heliospectra’s proposed rights issue, fully secured by its main owner, Weland Stå...
Redeye offers a preview of Polygien's Q4 results set to be released on February 13.
The greatest excitement regarding Aspo's Q4 results faded when the company downgraded its full-year ...
Ahead of Atria’s Q4 report, we maintain our estimates intact.
Preliminary Q4 sales SEK 8.2m, cash balance SEK 17m '25e-'26e sales and EBIT unchanged, EPS changes ...
Q4 due on 13 February Negative organic growth but +14% adj.
Neovici AB (”Neovici” eller ”Bolaget”) är ett snabbväxande SaaS-bolag inom fintech som har utvecklat...
Redeye comments on Freemelt’s preliminary Q4 figures, which came in stronger than expected in terms ...
Redeye updates on EG7 ahead of Q4-results (due 7 February) where we expect continued sequential resu...
Redeye provides its comment on the news of the severe adverse event that occurred in the use of off-...
Mangold uppdaterar sin syn på greentech-bolaget ChargePanel efter det största avtalet i bolagets his...
